Start here if you're new
what it is
It sells lab tools, chemicals, and testing services to scientists, drugmakers, and hospitals.
how it gets paid
Last year Thermo Fisher Stfc made $44.6B in revenue. Laboratory Products and Biopharma Services was the main engine at $24.08B, or 54% of sales.
why it's growing
Revenue grew 3.9% last year. The $6.57 EPS print mattered because it beat $6.45 and gave management room to raise full-year 2025 revenue guidance to $44.1B-$44.5B.
what just happened
Thermo Fisher beat by $0.12 as EPS came in at $6.57 versus $6.45.
At a glance
A balance sheet — strong enough to weather a downturn
65/100 earnings predictability — reasonably predictable
27.5x trailing p/e — priced about right
0.3% dividend yield — cash in your pocket every quarter
12.0% return on capital — nothing to write home about
xvary composite: 79/100 — average
What they do
It sells lab tools, chemicals, and testing services to scientists, drugmakers, and hospitals.
54% of 2024 sales came from Laboratory Products and Biopharma Services. That is the refill aisle. You keep buying because stopping a lab costs more than switching vendors. Another 19% came from Life Sciences Solutions, so the business has two big lanes, not one gimmick.
How they make money
$44.6B
annual revenue · their business grew +3.9% last year
Laboratory Products and Biopharma Services
$24.08B
Life Sciences Solutions
$8.47B
Analytical Instruments
$7.58B
Specialty Diagnostics
$4.46B
The products that matter
lab instruments and consumables
Life sciences tools
$44.6B revenue base
it's the core engine of the business: a $44.6B revenue platform serving labs that need equipment, reagents, and workflow continuity more than they need a cheaper vendor.
core
clinical trial data services
Clario deal
~$1.25B target revenue
Clario is not closed yet, but management expects the deal by mid-2026 and says it could add roughly $0.45 a share to adjusted earnings in the first 12 months after closing.
next lever
pharma and biotech customer base
End-market exposure
70% of revenue
this is not a product line, but it is the key economic fact. When 70% of your revenue comes from one customer group, that group effectively becomes a business segment whether the company labels it that way or not.
the real split
Key numbers
$44.6B
annual revenue
That is the size of the machine. A 3.9% lift on this base adds roughly $1.7B.
26.5%
operating margin
You keep 26.5 cents of every sales dollar before interest and taxes. That is why the business throws off real profit.
$31.9B
long-term debt
That is the balance sheet bill. It equals 12% of capital, so leverage matters even with an A-grade balance sheet.
12.0%
return on capital
For every $100 invested in the business, Thermo Fisher earns $12 back. That is solid, not heroic.
Financial health
A
strength
- balance sheet grade A — very strong financial position
- risk rank 2 — safer than 80% of stocks
- price stability 75 / 100
- long-term debt $31.9B (12% of capital)
- net profit margin 20.7% — keeps 21 cents of every dollar in revenue
- return on equity 16% — $0.16 profit for every $1 investors have put in
A with balance sheet grade and risk rank standing out. your money faces less risk here than at most public companies.
Total return vs. market
You invested $10,000 in TMO 3 years ago → it's now worth $10,950.
The index would have given you $14,770.
source: institutional data · total return
What just happened
beat estimates
Thermo Fisher beat by $0.12 as EPS came in at $6.57 versus $6.45.
Revenue was $32.3B, and management lifted 2025 guidance to $22.60-$22.86 per share and $44.1B-$44.5B in sales. The market pays for beats and raises, and this report gave it both.
$32.3B
revenue
$6.57
eps
1.86%
earnings surprise
the number that mattered
The $6.57 EPS print mattered because it beat $6.45 and gave management room to raise full-year 2025 revenue guidance to $44.1B-$44.5B.
-
management slightly upped its full-year 2025 outlook for thermo fisher scientific in late october.
-
leadership said it saw the massachusettsbased lab equipment maker earning between $22.60 and $22.86 a share on an adjusted basis, up 3.4%–4.6% from 2024’s $21.86 tally and modestly above its previous $22.22–$22.84 target range and the 1.6%–4.5% bottom-line growth that it implied.
-
key assumptions underlying the executive team’s october profit forecast were $44.1 billion–$44.5 billion in overall revenue (up 2.8%–3.8%, vs. prior year) and modest profit-margin expansion.
-
the company’s projections have decent upside.that’s because they don’t yet reflect any contribution from clario holdings, the private equity-backed provider of clinical-drug-trial data solutions that thermo hopes to acquire by mid-2026 (in a deal worth up to $9.4 billion, including future earn outs).
-
clario likely generated about $1.25 billion in overall revenue last year.it should add roughly $0.45 a share to thermo’s adjusted earnings within the first 12 months of the deal’s closing. leadership recently held a view that organic, top-line growth (excluding currency and m&a effects) will accelerate pretty dramatically over the next several years.
source: EDGAR filing and Yahoo Finance, latest quarter
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is pharma and biotech spending concentration.
med
pharma budget slowdown
70% of Thermo Fisher's $44.6B revenue comes from pharma and biotech customers. That is scale, but it is also concentration.
If that customer base slows spending, the majority of the revenue base feels it at once.
med
Clario integration risk
Management expects Clario to close by mid-2026 and says it could add roughly $0.45 a share to adjusted earnings in the first year. Deals always look cleaner before the integration starts.
A delayed close or messy integration would push expected earnings support further out.
med
margin normalization
Trailing net profit margin is 20.0%, but the latest quarter came in at 14.5%. One quarter does not make a trend, but it does tell you the margin profile is not untouchable.
If quarterly profitability keeps landing closer to 14.5% than 20.0%, the 27.5x earnings multiple gets harder to defend.
Because 70% of revenue comes from pharma and biotech, the key risk is not abstract. It touches most of the $44.6B business directly.
source: institutional data · regulatory filings · risk analysis
Pay attention to
risk
pharma and biotech demand
70% of revenue comes from this customer group. If budgets tighten, you will see it here first.
calendar
Clario closing timeline
Management expects the deal by mid-2026. Timing matters because the expected ~$0.45 adjusted EPS benefit starts only after closing.
metric
full-year revenue guide
The current range is $44.1B–$44.5B. That is your reality check on whether the base business is merely steady or starting to slip.
trend
margin recovery
Trailing net margin is 20.0%, but the latest quarter was 14.5%. You want that gap narrowing for the right reason.
Analyst rankings
short-term outlook
top 20%
momentum score 2 — analysts expect above-average price performance in the year ahead. in human-speak, they like it.
safety profile
above average
stability score 2 — historically safer than roughly 80% of stocks. Not a bunker, but not fragile either.
chart momentum
average
technical score 3 — the stock is acting normal. No obvious breakout, no obvious breakdown.
earnings predictability
65 / 100
These earnings are reasonably forecastable, but not machine-like. Expect some noise around the edges.
source: institutional data
Institutional activity
institutions have been net buying for 2 consecutive quarters — 1,188 buyers vs. 1,075 sellers in 3q2025. total institutional holdings: 0.3B shares. net buying for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$483
$885
$627
current price
$684
target midpoint · +9% from current · 3-5yr high: $1085 (+75% · 15% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive